Navigation Links
GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting
Date:8/27/2010

ATLANTA, Aug. 27 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today announced the results of its Annual Shareholders Meeting, held on August 24, 2010.

During the meeting, shareholders re-elected seven nominees for directors of the company to serve until the 2011 Annual Meeting of Shareholders and until their successors are duly elected or appointed and qualified. They are:

  • Donald G. Hildebrand, Chairman of the Board of Directors
  • Robert T. McNally, Ph.D., President and CEO
  • Harriet L. Robinson, Ph.D., Chief Scientific Officer
  • Steven S. Antebi, Independent Director
  • David A. Dodd, Independent Director
  • Dean G. Kollintzas, Independent Director
  • John N. Spencer, Jr., CPA, Independent Director

  • Additionally, stockholders ratified the appointment of Porter Keadle Moore LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2010.

    Don Hildebrand, company co-founder and Chairman of the Board of Directors, provided opening remarks and conducted the formal business of the meeting.

    In addition to the business of the annual meeting, Robert McNally, president and chief executive officer, provided an overview of the company's progress, highlighting GeoVax's performance since the last annual meeting held in June 2009. He discussed significant scientific outreach including conferences where GeoVax participated in presenting advances in vaccine development, and improvement in corporate communications through a new public and investor relations firm, IRG.  Dr. Harriet Robinson, company CSO, discussed clinical and research progress including the current status of the Phase 2a Preventative Vaccine Trial including the expansion from 225 to 300 part
    '/>"/>

    SOURCE GeoVax Labs, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
    2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
    3. GeoVax Presents Data at AIDS Vaccine 2008 Conference
    4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
    5. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
    6. GeoVax to Present at the BIO CEO & Investor Conference 2009
    7. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
    8. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
    9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
    10. GeoVax Labs, Inc. Announces First Quarter Financial Results
    11. GeoVax to Exhibit at the 2009 BIO International Convention
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... A new study by researchers from the University ... tiny nanosystems function, unlocking the potential to create ... study, which has been published in the prestigious ... a novel laser technique to examine in rich ... a small cluster containing an acetylene molecule and ...
    (Date:7/25/2014)... WABC Radio show out of New York City, ... will be hosting California-based Vet-Stem, Inc.’s Founder and CEO, Robert ... pets. Dr. Harman first visited the show in November ... pets suffering from osteoarthritis and other degenerative diseases, as well ... , Young has invited Dr. Harman back to dial down ...
    (Date:7/25/2014)... 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... the development and commercialization of a once-daily, oral therapy ... today announced financial results for the period ended June ... , Reported cash and cash equivalents totaling $37.4 ... December 31, 2013.  , Reported a net loss ...
    (Date:7/25/2014)... Biotech Ltd. (Nasdaq: SVA ), a leading provider ... announced that it will release its unaudited financial results for ... on Thursday, August 14, 2014 EDT. The Company will host ... August 15, 2014, at 8:00 a.m. EDT (Friday, August 15, ... Company,s financial results and provide an update on recent corporate ...
    Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2
    ... Researchers Comprise One of the Main User Groups of febit,s ... Simplified and Automated Microarray Technology, MEDFORD, Mass., ... it will introduce the Geniom RT Analyzer(R) to,the U.S. market ... in Boston., RNA-researchers, one of the main user groups ...
    ... SANTA CLARA, Calif., April 22 /PRNewswire/,-- Agendia BV, ... of molecular,diagnostics, and Agilent Technologies, Inc. (NYSE: ... to collaborate to develop new in-vitro,diagnostic tests. In ... Agendia products will continue to be supplied on ...
    ... SUPG ), a pharmaceutical company dedicated to the discovery, ... malignancies, invites all interested parties to listen and,view a ... at 9:30 a.m. ET,(6:30 a.m. PT) to approximately 12:00 ... Investors and interested parties may access the webcast ...
    Cached Biology Technology:febit to Introduce Geniom RT Analyzer(R) to U.S. Market at RNAi World Congress 2febit to Introduce Geniom RT Analyzer(R) to U.S. Market at RNAi World Congress 3Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement 2Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement 3
    (Date:7/25/2014)... a pleiotropic factor characterized by the existence of ... that confer to the protein deeply different characteristics. ... myelination occurring during development and the different phases ... degeneration, axon regrowth, remyelination and target reinnervation, Researchers ... that the soluble NRG1 upregulation observed in Schwann ...
    (Date:7/25/2014)... of a molecular testing panel developed at UPMC ... initial surgery for patients with thyroid nodules and ... Cancer Institute (UPCI), partner with UPMC CancerCenter., The ... and other diagnostic testing agencies, improved the chances ... 30 percent, according to the study published this ...
    (Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
    Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
    ... , AMIA, the association for professionals in biomedical and ... the National Coordinator on Health Information Technology (DHHS/ ONCHIT), ... meaningful use of electronic health records (EHRs) over the ... Policy Committee (HITPC), on the continuation of support for ...
    ... When patients receive a bone marrow transplant, they are getting ... are needed when a patient is low on red blood ... be caused by cancer or even cancer treatments such as ... transplant might not succeed because the transplanted stem cells don,t ...
    ... Spanish . Fernando Rendo, biologist at the ... with the intention of completing the genealogical tree ... Country Autonomous Community (CAPVEAE) and Navarre. Concretely, he opted for ... (a kind of variation in the DNA sequence) that can ...
    Cached Biology News:AMIA on meaningful use: Invest in people and technology 2How long do stem cells live? 2Basque thesis investigates wide diversity within certain ovine, bovine and equine breeds 2Basque thesis investigates wide diversity within certain ovine, bovine and equine breeds 3
    MitoScreen (JC-1) Kit , 100 tests Consult technical datasheet for details....
    Large-fragment, single-stranded carrier DNA of the highest quality, perfectly suited for all types of yeast transformation....
    ... , Customer Peptide Synthesis , 20 Amino Acid length ... 20 mg will return to customer for future usage conjugation ... , Maintenance 102 days/each , ... x5 /each , Test bleed (app. 5 ml) ...
    Request Info...
    Biology Products: